Novo development exec: ”I’m looking at a rich pipeline across all therapy areas"

Pharmaceutical firm Novo Nordisk is heavily expanding when it comes to disease areas and technologies. The man tasked with the job looks ahead to a bright future, while not pre-emptively betting on any specific candidate.

Martin Holst Lange, executive vice president of development at Novo Nordisk | Photo: Novo Nordisk / PR

Novo Nordisk is forging a future beyond the patent expiration for its lucrative molecule semaglutide, which is behind the company’s best-selling drug by some distance, diabetes treatment Ozempic, which sold for DKK 33.7bn (USD 5.2bn) in 2021 alone.

With the goal of securing a post-semaglutide future, Novo Nordisk is searching far and wide – not just for one candidate but for a long list of new drugs to compensate for the enormous gap that will be left once the semaglutide patent runs out.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs